News

Treatment with Eli Lilly’s monoclonal antibody Taltz (ixekizumab) significantly improved the signs and symptoms of ankylosing spondylitis in patients participating in a Phase 3 clinical trial, results show. The study, called COAST-W (NCT02696798), met its primary and major secondary endpoints, Eli Lilly said in a news release. COAST-W, the second Phase 3…

Use of nonsteroidal anti-inflammatory drugs (NSAIDs) in addition to tumor necrosis factor (TNF) inhibitors provides stronger long-term protective effects in patients with ankylosing spondylitis, according to recent clinical trial results. The combo therapy prevented radiographic progression of the disease significantly during a four-year period compared to NSAIDs or…

Ontario, along with other regions in Canada, will now reimburse Cosentyx (secukinumab) under its public drug program for certain adult patients with ankylosing spondylitis (AS) and active psoriatic arthritis (PsA), Novartis Pharmaceuticals Canada recently announced. In addition to Ontario, Cosentyx will also be available through the public…

Latest clinical data on Cosentyx (secukinumab) demonstrates its long-term potential to prevent radiographic progression and improve the quality of life of patients with ankylosing spondylitis. Several relevant studies were presented recently at 2018 Annual European Congress of Rheumatology (EULAR), held in Amsterdam, The Netherlands. Cosentyx is a specific…

The investigative therapy bimekizumab showed significant potential in reducing disease activity and it provided clinically meaningful improvements in ankylosing spondylitis (AS) patients, according to Phase 2b clinical trial data. UCB Pharma recently presented the trial’s findings in a study, “Dual Neutralisation of IL-17a and IL-17F with Bimekizumab in…

Women, compared to men, have a reduced response to certain ankylosing spondylitis treatments, a study has found. The study “Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort” was published in the Journal of Rheumatology. While ankylosing spondylitis has…

A mutation considered to be a risk factor for ankylosing spondylitis has now been questioned in a new large population study. The study, “Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis,…

Social media data has allowed scientists to examine ankylosing spondylitis patients’ knowledge, attitudes, and beliefs regarding biologic therapies. The study, “Patients’ Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights from a Large-Scale Survey of Social Media Platforms,” was published in the journal Arthritis Care &…

Ankylosing spondylitis patients carry a significantly higher burden for several comorbidities — other diseases — than are found in people without this inflammatory disorder of the same age and sex, a study drawing on real-world medical data reports. Comorbidities seen to have the highest incidence rates among ankylosing spondylitis patients…

The European Medicines Agency has accepted for review Lupin‘s marketing authorization application for YLB113, a biosimilar of etanercept that is marketed by Amgen under the brand name Enbrel. YLB113’s application is for the treatment of ankylosing spondylitis, axial spondyloarthritis, and non-radiographic axial spondyloarthritis, as well as rheumatoid and psoriatic arthritis…